Selank is a synthetic anxiolytic peptide derived from the human immunoglobulin G (IgG) molecule tuftsin. It has been extensively studied in preclinical and clinical research for its potential effects on anxiety, stress, and cognitive function, without the sedative side effects often associated with traditional anxiolytics.
Selank’s primary mechanism of action is thought to involve the modulation of GABAergic and serotonergic systems in the brain. It interacts with GABA receptors, increasing their binding affinity, and also influences the metabolism of enkephalins. These actions contribute to its anxiolytic, antidepressant, and mild nootropic effects.
Clinical and preclinical research has explored Selank in the context of:
Its unique profile as an anxiolytic without significant sedation makes it a subject of considerable interest for both mental health and nootropic research.
Selank’s regulatory status may vary depending on jurisdiction and current policy. In some countries (e.g., Russia), it is approved as a pharmaceutical drug. However, in many other regions, it is considered a research chemical and is not approved for human therapeutic use. Researchers should consult the latest guidelines from regulatory bodies for specific guidance. For a general overview, refer to our U.S. peptide legal status tracker.
Researchers comparing Selank products often evaluate:
PeptideChecker tracks Selank product listings across multiple suppliers to help researchers compare availability, pricing, and quality.
Q: What is Selank primarily used for in research? A: Selank is extensively studied for its potential roles in anxiety reduction, stress management, and cognitive enhancement.
Q: How is Selank typically administered in research settings? A: Common administration routes in research include intranasal administration and subcutaneous injection.
Q: Where can I find verified suppliers for Selank? A: Our supplier comparison tool provides a list of vendors offering Selank with purity and pricing details.
\n\n